RenovoRx (RNXT) announced that Johns Hopkins Medicine is now initiated to enroll patients with locally advanced pancreatic cancer in the ongoing Phase III TIGeR-PaC clinical trial. The trial is evaluating RenovoRx’s intra-arterial delivery of gemcitabine via the RenovoCath device. Johns Hopkins Medicine’s Valerie Lee was appointed Principal Investigator for the site. RenovoRx expects full enrollment in the trial during 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx Reports Initial Revenue and Clinical Trial Progress
- RenovoRx increases production of RenovoCath
- RenovoRx: Promising Phase 3 Study and Revenue Growth Drive Buy Rating
- RenovoRx Delays Yearly Report Filing
- RenovoRx’s Innovative Approach to Pancreatic Cancer Treatment: A Promising Investment Opportunity
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue